...5...5...7 SARS...8 2003...9...10...12...13...14...14...15...17...19 SARS...20...22...24...24 SARS...25 N95...26...28
...28 ( )...29?...29...30...30...31...31...34...35...36...36...38...39...40...41 &...42...42...47...56...67
...67...70...71 ( )...73...73...73...74 1918...74...74...76...78...79...82...84...84...84...84...85...85 Influenza Surveillance...86
SARS...87...87 SARS...88...88...88 SARS...89...90 SARS...91 SARS...91...92 SARS...92 SARS...93...94
( ) 138 p.115. 50% (CDC) CDC 2004 CDC CDC VRSA CDC 1000 MT, S.auresus VRE
, 1000,,, CDC PP.116-117 0 10
16 MRSA VRE : 2003 2004 SARS 94% 2003 3 1 7.72 3.98 5 17 18 49 A B 5 8 9 49,
5 20032004 A B 20228 10000 5 7 87% ( ) ( SARS 20032004 2003 6 30 SARS SARS SARS SARS SARS SARS N95 SARS SARS 100 6 4 2002 SARS N95 N95 SARS
SARS 30 40 4 2003 / / 40 11 16 70% 6 3 50% 1 1 100% 95% 1 0% 3 1 33% 1 1 100% / 3 1 33% 55 13 21 62% / / 1 1 100% 5 2 40% 4 1 25% 4 2 50% IA 1 1 100% 15 1 6 47% 95% / / 1 1 100% 1 0% 95%
2 1 50% / / 95% 72 15 27 42/72=58% PPE - - - --
N95 - -
98 12 -- -- -- 74 8 FluMist 2000 38% Flu Mist FluMist --
FluMist 517 5064 5 / ( ) SARS ------------- SARS SKW, SSC, YM. N Engl J Med 2003; 349:187-188 SARS SARS SARS SARS SARS SARS 2003 3 5 4 13 SARS SARS SARS
2002 SARS SARS SARS SARSSARS ( ) 89 ME ] 1991 1990 6 e
1972 1999 30 1966 needlestick www.hiconline.com 2000 10 28 1993
( )
( ),,, FAAN, 8 2004 NMWR 1996 SARS 911 92
1996 250 600 ( ) SARS SARS,, SARS SARS 8893 SARS SARS 3 5 SARS
SARS SARS 10 SARS SARS SARS 2003 6 5 345% SARS 24 70% () 30% SARS A B, SARS N95 SARS www.hiconline.com, 2003 6.
SARS 1 2 SARS 4 6 1 2 3 7 SARS SARS 14 16 15% SARS SARS SARS SARS ( ) 22
,,,, 39 22 100% 58% 1998 911 430 3 4 38 69, 3 27 26 4
26 23 88% 23 8 ( ) SM Clin Infect Dis20033610181029 PDAs epocrates epocrates ABX 2002 IDAN Palm OS Pocket PC ABX 50 ABX epocrates IDAN IDAN ABX PDA epocatesabx, IDAN
ipocrates 300 ABX ABXePocrates IDAN ALAN D. TICE, MD, FACP EPocrates PDA SARS epocrates Merckmedicus Theradoc Starbucks ( ) SARS 2003 6 4 WER http://www.who.int/csr/doncdc. MMWR. Morb Mortal Wkly Rep. 2003;52:500-501 6 2 29 8384 770 27 SARS SARS Co-V SARS Co-V SARS M G PCR SARS
SARS 10 SARS 10 MMWR 41 363 SARS 297 82 66 18 32 48 SARS Co-V 7 7 4 12 3 46 14 2825 41 14 1 PCR SARS 46 SARS SARS CDC 21 B SARS SARS 10 15 SARS SARS SARS ( ) N95 N-95 N-95 APF N-95 20% 10% APF A5 10% APF APF 5 1/5 APF TB
APF APF APF 5 APF 10 APF 5 -- Z88 2 5 10 APF 10 APF 5 APF 10 APF 10 APF N95 N100 N 95 N95
N95 ( ) Clin Infect Dis. 2003 ;36 :1383-1390 0.1% 282 10% 13% 12% 2% 32% OR 3.0 ; 95% CI, 1.8-4.9 OR 0.3% ; 95% CI, 0.2-0.6
J.R.R. Tolkien The Lord of Rings ( )? B Emerg Infect Dis.2003 www.cdc.gov/ncidod/eid/vol19no7/03-0065.htm (AAB) VAP 310 AAB 864 10 Legionella anisa Bosea massiliensi BAL Acanthamoeba polyphaga AAB 30 66 BAL PCR L anisa B massilensis DNA 30 12 1 AAB L anisa B massilensis ( )VAP B BAL AAB B massilensis ( ) L anisa Pontiac fever Lefionnairs disease ( )
摘要和注释 El-Solh AA Am J Respir Crit Care Med20031671650-1654 El-Solh 78% X 57% 20% 80% - 49% ( ) Gram-negative enterics16% 12% Staphylococcus aureus E colik pneumoniaeserratia spp,p mirabilis; P (P aeruginosa) (Enterobacter cloacae)s (Staphylococcus aureus), (Streptococci)S (S pneumoniae), Prevotella spp, (Fusobacterium )spp, Bacteroides spp, (Peptostreptococcus) spp, (percutaneous gastrostomy) (Periodontal disease),,,,, 43% (pulmonary infiltrates), El-Solh :,,, (aspiration) (,, ),,, (oropharynx aspiration),,,,
protected brush catheter Bartlett Bartlett X ( ) - - 2001 66.4 48.7 40.6 - [ ] [ ]
24,000 455,000-291,400 - T -
81 88 41 20 24 28 79 46 -
/ ( ) DNA 21 79 31
800. ( ) 240 27 8.
30 30 2003 5 15 1999 1 2 3 4 5 6789 200 1 2 3 4 27 45
30 30%--40% 30 15 30 2002 3 2002 MMC 1999 1 2 3 4 1986 12 12 5
2001 11 / MMC 2003 4 / MMC *
* * * * { } * 54 54/1413 2001521 54 WHA48/7 WHA48/13 WHA51/17 1. 1 2 3 2.
3. 1 2 3 4 5 6 521 A54/VR/9 CSR ----- CSR * CSR C * --- CSR --- CSR *
21 1 2 200 191 CSR CSR CSR CSR CSR CSR
CSR & 191 WHO WHO1997 ---
. WHO WHO,
--- GPHIN GPHIN 600 GPHIN WER 80 http:www.who.int/wer/emc/outbreak-news/index.html http:www.who.int/wer/index.html
. 199771 19997 246 246 43% 12%11% 9% 121 49% 6 2% 78 24 22 0.8% ( 2) 71% 29% 134 18 1 25 13 15 2035 50 48 3 69 246 199771 199971 69 69 58 84% 6% 10% 69 246 62 /
1997 72% 70% 1%
WHO 1. 2. 3. 4. 5. 6. 7. 8. 8..1 8.2 8.3 8.4 9. 9.1 9.2 10. 11. 12. 1 1.
19 1907 1315892 1918 2000 1919 1948 191 IHR 20 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 2. 2.1
2.2 2.3 [2.1][2.2] 3. NGOs 1950 191 OV GPHIN
900 4. 5.
6. 7. 8.. 3......... - - - -
- - - - - - - - - - 8.1.1.1 8.1.2... 2005 < >.,,,. 8.1.3 8.2.2.1 8.2.2 / 8.2.3 8.2.4
8.2. 8.3 8.4 8.4.1 8.4.2 8.4.3 8.4.4 9. 9.1
24 92 10.
11. 12. 1 20009 2 200012 3 200012 4 200012 5 2000 001 6 - - - 200012 - - - 7 200012
8 20016 9 200011 10 20013 2001 6 7 A 1997 1997, 314334382000 8 19981999 1998
1999 229 111 9 1 1 Cyclosora Campylobacter BSE BSE vcjd( ).2000 10 BSE BSE vcjd. BSE 3 50. 15 29. 10% 2000 7%.,. BSE 200 1997
Mae Sot Thi Lo Su GDP GDP.. 25%, 5%8% 1965 1990 GDP. 22000000 20 2010 8% 0.4% 25% 1% 8.5%18.3%. 1997 18 6 1500000 104000000 2001 5 1000000. 1991 4500 10400 1991 60%70% 700000000
52562000 6 1961 1956 1966 2.8 1961 1966 5.8 19 50 50 32,000,000 26 1967 1,350,000,000 23000000 13 1967 1979 300000000 /
WHO 1999 2001 (http://www.who.int/infectious-disease-report/) 2001 ASEAN 2001 BIMST: BIMST 2000 NGOs 2010 25% 50% 2001 : 1,300,000,000 (UNGASS) 2001 6 / /
E. 21 1997 ISTWG, ISTWG 1
/ http:/ /www. cdc.gov/ncidod/eid, 500 2
71 1998 71 1997 1998 CDNA 1989 -- CDNA CDNA CDNA SPC CDNA CDNA CDNA 3 (,,, ).
( 71),,, 1997 (). 1997,..1997 1500000 1997 10 2001 5 4 EI
MAE [WHO] (TEPHINET) MAE WHO WHO MAE MAE WHO 1997 6 TEPHINET 17 WHO TEPHINET TEPHINET NIH NIH 5
APEC APEC APEC APEC APEC APEC 6 APEC APEC 21 APEC APEC
APEC 2001 6 2000 2001 APEC 2002 2002 6 14 2002
31 50 50 1998 1999 2000
10.5% 30% 5 5 1. C, J J 2. D A. 3. S S A.
727 30 2001 2005 50% 13 185 8%. 2005 185 180 1996 15 4 1997 2001 50% 5% 20 90 2003 900 50% 2001 3 8 300
1. DR SD 2005 50% 2. RS, DR Ro, 1994 2000 2000 12 76 5559 25% 1993 25 1994 2000 42% 15% 9% 2002
5 1997 2000 653 2001 20 90 2001 2001 2 5721 6949 PLWA 1. LM. 25 19942000 MMWR2003;52(27):634-636 2. R. 3. DG AM
( ) 8 BC 8 J Clin Microbiol. 2003 ;41:2156-2157 HCW 8 236 0.4%4.7% 152 0.7%2.0% 72 8 6.9%12.5%31% 8 HHV-8 2.5 8 KSHV 8
1918 1918 2001 5 1918 2000 4000 1918 25 50 1918 1918 1918 1918 H1N1 1918 1918 20 50 1918
1918 66 20 1918 2 9 20 90 H5N1 1 4 48 89000 207000 314000 734000 18 4200000 2000 47000 ( 15) 84 1918 6
8 1918 1918 1918 1918 7 (1) (2)
(3) (4) (5) (6). 2002 2002 2 911 X 60 X 60
5 2002 2 1 30 45 75 115 500000 2003 7 18 38000 2003 7 24 10000000
50000 50 000 10 1000 74 18000000 2003 1 2 6 3 4 24 23 5 6 290000 100 2002 11
14 5 2500 (47 53 ) 50 500 15 36 000. 24 24
CDC
10 10 10 12 West Nile Virus Yellow Fever O157 SARS 6 10 6 15
77 5 5 297 90%11 10 4 25 30 2-a 10 Biken 30 30 17D 1. << >>.http://www.cdc.gov/ncidod/dvbid/jencephalitis/index.htm. 2. SA, W.<< >>.Emerg Infect Dis.2001;
7 :900-903. 3. Dresinski S. << >> Infectious Disease Alert.2003;22:129-130. 4..T.<< 2-a : >>.Lancet.2003;361:821-826. 5. Monath.TP. << : >>.Curr Top Microbiol Immunol.2002;267:105-138. 摘要与注释 Barmah Barmah NSW., Barmah., 370. Barmah. 5000,.,. Culex Aedes,...,,., []..,.,..,,. Barmah,,.,,.2002 95% 90% 73%
Influenza Surveillance WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia National Scientific Center for Virology and Vector Borne Disease E-mail
SARS 7 10 2003 424 6945 SARS 7 5 WHO SARS SARS 200 SARS SARS SARS SARS SARS SARS 121 SARS SARS SARS SARS SARS 422 247 2003 SARS SARS SARS SARS
SARS (423 471 2003 ) 2000 145 SARS SARS 1918 SARS SARS SARS SARS 2003 50 SARS SARS WHO SARS
WHO 1918 SARS WHO SARS 1918 SARS WHO SARS SARS SARS WHO 3 15 SARS WHO WHO 5 24 SARS (CDC) 4 2 CDC SARS AIDS HIV SARS 5 200 7 15 SARS SARS R 0 R 0 5 23 SARS R 0 2 4 R 0 10 1 R 0 1 SARS SARS
SARS 321 SARS SARS SARS SARS SARS SARS SARS SARS SARS 5 SARS SARS SARS SARS SARS WHO SARS WHO SARS PCR PCR CDC SARS SARS WHO SARS WHO SARS
SARS SARS WHO SARS SARS SARS SARS X SARS 10 65 SARS SARS a coup de gr ce SARS SARS 11 SARS SARS 5 SARS
SARS SARS SARS SARS 1998 SARS 54 11 732 SARS SARS SARS SARS 1957 1968 1997 2001 SARS B3 SARS HIV
SARS 14 SARS SARS SARS 1000 HIV 1984 SARS SARS 29 SARS SARS SARS SARS 300000 SARS SARS SARS
SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS SARS
Hangzhou Neuro-Hemin Biotech Co., Ltd International Society for Infectious Disease